the American laboratory Pfizer records a 78% jump in its profit

Published on :

Global demand for coronavirus products remains strong. The laboratories are therefore posting record results. In particular, Pfizer, which recorded a 78% jump in its profit, thanks in particular to its vaccine and its anti-Covid pill.

The American laboratory anticipates sales of up to 54 billion dollars in 2022. Upon the announcement of these results, the title of Pfizer increased by 1%.

► To listen: Pfizer, 162 years of “magic potions” in the United States

Sales of the anti-Covid vaccine are behind much of its growth and its revenue should be further boosted by the antiviral treatment, marketed under the name Paxlovid.

Sales of the drug jumped following an upsurge in cases in the United States and elsewhere around the world. It was notably used to treat the American president, Joe Biden.

In June, Pfizer and its German partner BioNTech have signed a contract worth more than 3 billion dollars with the US government for the delivery of 105 million doses of their vaccine adapted to the Omicron variant. It is still awaiting marketing authorization.

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick